About AnchorDx
AnchorDx is a Healthcare company based in Guangzhou (China) founded in 2015. High-throughput gene sequencing platform is developed for clinical diagnostics. AnchorDx has raised $73 million across 3 funding rounds from investors including Orbimed, Arch Venture Partners and Frontline BioVentures. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics.
Company details
AnchorDx was founded in 2015 in Guangzhou, China, within the biotechnology sector focused on genomics. A high-throughput gene sequencing platform is developed for clinical applications, supporting early detection of genetic diseases. Proprietary tests are offered, including non-invasive prenatal testing, pre-implantation carrier screening, cancer diagnostics, and liquid biopsy analyses. Operations emphasize intervention to lower disease incidence through accessible sequencing technologies.
- Headquarters Guangzhou, China
- SectorsHealthcare
- Website anchordx.com
- Total Equity Funding$73M (USD)
in 3 rounds
- Latest Funding Round$40M (USD), Series C
Feb 2021
- InvestorsOrbimed
& 5 more
Funding Insights of AnchorDx
AnchorDx has successfully raised a total of $73M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $40 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $73M
- Total Rounds 3
- Last Round Series C — $40M
- First Round $5M
(Dec 2015)
- Investors Count 6
All 3 funding rounds of AnchorDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2021 | $40M | Series C | – | Orbimed | – |
| Nov 2017 | $28M | Series B | – | Frontline BioVentures | |
| Dec 2015 | $5M | Series A | – | – |
6 investors in total: 6 institutional.
Investors in AnchorDx
AnchorDx has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Arch Venture Partners and Frontline BioVentures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
| frontlinebioventures.com | ||||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
| marathonvp.com | ||||
Provider of early stage venture capital focused on technology companies | nlvc.com | Menlo Park, United States | ||
Develops and manufactures APIs, finished dosage forms, and biologics. | 2000 | wuxipharmatech.com | Shanghai, China |
Investor details for AnchorDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AnchorDx
1 people are tracked at AnchorDx (1 in leadership).
| Name | Role | Group |
|---|---|---|
Jianbing Fan | CEO and Founder | Leadership |
Complete people profiles for AnchorDx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AnchorDx
3 dated milestones of AnchorDx across 6 years, from founding to its latest funding, stage changes and deals.
- Founded AnchorDx is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Series C, of $40.0M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Anchordx
Complete news archive for AnchorDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AnchorDx
AnchorDx was founded in 2015.
AnchorDx is headquartered in Guangzhou, China. It is registered at Guangzhou, Guangdong, China.
AnchorDx is a funded company, having raised a total of $73M across 3 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Dec 2015.
AnchorDx was founded in 2015 in Guangzhou, China, within the biotechnology sector focused on genomics. A high-throughput gene sequencing platform is developed for clinical applications, supporting early detection of genetic diseases. Proprietary tests are offered, including non-invasive prenatal testing, pre-implantation carrier screening, cancer diagnostics, and liquid biopsy analyses. Operations emphasize intervention to lower disease incidence through accessible sequencing technologies.
AnchorDx has 6 investors. Key investors include Orbimed, Arch Venture Partners, Frontline BioVentures, WuXi PharmaTech, and Marathon Venture Partners.